|
Orthologous residues
|
|
RXRA (human): S260‑p, RXRA (mouse): S265‑p, RXRA (rat): S265‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, mutation of modification site
|
|
Relevant cell lines - cell types - tissues:
HPK1A (keratinocyte)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
ERK1 (human)
|
transfection of inactive enzyme, pharmacological inhibitor of upstream enzyme, transfection of constitutively active enzyme
|
|
|
KINASE
|
ERK2 (human)
|
transfection of inactive enzyme, pharmacological inhibitor of upstream enzyme, transfection of constitutively active enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
PD98059
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
inhibition
|
|
Comments:
Phosphorylation of hRXRalpha resuts in attenuated transactivation by the VDR and resistance to the growth inhibitory action of 1,25(OH)2D3 and RXR-specific agonist LG1069.
|
